adhera therapeutics
Missing: adhera therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: adhera therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest adhera therapeutics News
May 19, 2022
Adhera Therapeutics ( OTCPK:ATRX +10.9%) is pleased to announce the appointment of Trond K. Waerness as Chairman of the Co.’s Board of Directors . Mr. Waerness has been serving as a Director at Adhera since April 2021, will be replacing Andrew Kucharchuk, who will remain CEO and Vice-Chairman. The Co. has also nominated Zahed Subhan, who currently serves on Adhera’s Board of Directors, as interim Chief Scientific Officer. “Trond is the ideal Chairman to lead Adhera as we move our lead drug candidates for Type 1 diabetes and Parkinson’s disease into mid-stage clinical trials and work to uplist our company to the NASDAQ exchange.” said Andrew Kucharchuk. To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
adhera therapeutics Frequently Asked Questions (FAQ)
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.